Increased dose single-agent gemcitabine in platinum-taxane resistant metastatic ovarian cancer

Basit Öğe Kaydı
dc.authoridHacıbekiroğlu, İlhan/0000-0002-0333-7405
dc.authoridCicin, Irfan/0000-0002-7584-3868
dc.authorwosidHacıbekiroğlu, İlhan/JCN-7264-2023
dc.authorwosidErdogan, Bulent/AAA-9781-2021
dc.authorwosidCicin, Irfan/AAQ-5575-2020
dc.contributor.authorKodaz, Hilmi
dc.contributor.authorHacibekiroglu, Ilhan
dc.contributor.authorTurkmen, Esma
dc.contributor.authorErdogan, Bulent
dc.contributor.authorElpen, Cagnur
dc.contributor.authorUzunoglu, Sernaz
dc.contributor.authorCicin, Irfan
dc.date.accessioned2024-06-12T10:56:13Z
dc.date.available2024-06-12T10:56:13Z
dc.date.issued2015
dc.departmentTrakya Üniversitesien_US
dc.description.abstractBackground: In platinum-taxane resistant epithelial ovarian cancer (EOC), we aimed to determine the effectiveness. Patients and Methods: Between 2004 and 2013, patients afflicted with platinum-taxane resistant EOC and who were administered a 30-minute i.v. infusion of single-agent gemcitabine at a dose of 1,250 mg/m(2) on the 1st, 8th and 15th days, every 28 days, were examined retrospectively. Results: Twenty-six patients with platinum-taxane resistant EOC were included in the study. The overall survival (OS) was 48 months. The median survival after becoming platinum-taxane resistant was 16 months for the study population. Median time to progression (TTP) and median survival after becoming platinum-taxane resistant for patients who received second-line treatment were 3.3 months and 16 months, respectively; for patients who received third-line treatment with gemcitabine, these were 3.7 months and 19 months, respectively. Administration of gemcitabine as second- and third-line chemotherapy in platinum-taxane resistant EOC, provides similar TTP and OS outcomes (p = 0.4, p = 0.9) with a similar response and toxicity rate. Conclusions: Second- and third-line gemcitabine at a dose of 1,250 mg/m(2) on days 1 , 8 and 15 every 28 days as a 30-minute i.v. infusion in platinum-taxane resistant EOC is an effective treatment option with a tolerable and manageable toxicity.en_US
dc.identifier.doi10.5301/tj.5000209
dc.identifier.endpage40en_US
dc.identifier.issn0300-8916
dc.identifier.issn2038-2529
dc.identifier.issue1en_US
dc.identifier.pmid25702671en_US
dc.identifier.scopus2-s2.0-84930688902en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage36en_US
dc.identifier.urihttps://doi.org/10.5301/tj.5000209
dc.identifier.urihttps://hdl.handle.net/20.500.14551/19705
dc.identifier.volume101en_US
dc.identifier.wosWOS:000359658100017en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSage Publications Ltden_US
dc.relation.ispartofTumori Journalen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectChemotherapyen_US
dc.subjectGemcitabineen_US
dc.subjectOvarian Canceren_US
dc.subjectPhase-Iien_US
dc.subjectSalvage Chemotherapyen_US
dc.subjectPaclitaxelen_US
dc.subjectTherapyen_US
dc.subjectTrialen_US
dc.titleIncreased dose single-agent gemcitabine in platinum-taxane resistant metastatic ovarian canceren_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu